Sun BioPharma, Inc. Schedules Conference Call on November 12, 2020 to Report 2020 Third Quarter Financial Results
02 Novembro 2020 - 10:00AM
Sun BioPharma, Inc. (Nasdaq:SNBP), a clinical stage
biopharmaceutical company developing disruptive therapeutics for
the treatment of patients with pancreatic cancer, today announced
that it will host a conference call on November 12, 2020 at 4:30 PM
Eastern Time to discuss results for its third quarter ended
September 30, 2020.
Conference Call Information
To participate in this event, dial approximately 5 to 10 minutes
before the beginning of the call.
Date: November 12, 2020 Time: 4:30 PM Eastern TimeToll Free:
877-407-9205 International: 201-689-8054
The call will also be available over the Internet and accessible
at:
https://www.webcaster4.com/Webcast/Page/2556/38324
Conference Call Replay Information
Toll Free: 877-481-4010 International: 919-882-2331 Replay
Passcode: 38324
About SBP-101
SBP-101 is a proprietary polyamine analogue designed to induce
polyamine metabolic inhibition (PMI) by exploiting an observed high
affinity of the compound for the exocrine pancreas and pancreatic
ductal adenocarcinoma. The molecule has shown signals of tumor
growth inhibition in clinical studies of US and Australian
metastatic pancreatic cancer patients, suggesting complementary
activity with an existing FDA-approved chemotherapy regimen. In
clinical studies to date, SBP-101 has not shown exacerbation of the
typical chemotherapy-related adverse events of bone marrow
suppression and peripheral neuropathy. The safety data and PMI
profile observed in Sun BioPharma’s current clinical trial provides
support for continued evaluation of the compound in a randomized
clinical trial.
About Sun BioPharma
Sun BioPharma Inc. is a clinical-stage biopharmaceutical company
developing disruptive therapeutics for patients with urgent unmet
medical needs. The Company’s initial product candidate is SBP-101
for the treatment of patients with metastatic pancreatic ductal
adenocarcinoma, the most common type of pancreatic cancer. Sun
BioPharma Inc. is dedicated to treating patients with pancreatic
cancer and fully exploring SBP-101’s potential for efficacy in
combination with other agents and in treating other types of
cancer. SBP-101 was invented by Raymond J. Bergeron, Ph.D., a
Distinguished Professor Emeritus at the University of Florida. Sun
BioPharma has scientific collaborations with pancreatic disease
experts at Cedars Sinai Medical Center in Los Angeles, the
University of Rochester in New York, Scripps MD Anderson Cancer
Center in San Diego, California, the University of Florida, the
Austin Health Cancer Trials Centre in Melbourne, Australia, the
Ashford Cancer Centre in Adelaide, Australia, the Blacktown Cancer
and Haemotology Centre in Sydney, Australia and the John Flynn
Private Hospital in Tugun, Queensland, Australia. The Company’s
independent Data Safety Monitoring Board (DSMB) is Chaired by James
Abbruzzese, MD, Professor of Medicine, and Chief, Division of
Medical Oncology at Duke University School of Medicine. Professor
David Goldstein, FRACP, Senior Staff Specialist at the Prince Henry
& Prince of Wales Hospital / Cancer Care Centre in Sydney,
Australia is Co-Chair of the DSMB. Further information can be found
at: www.sunbiopharma.com. Sun BioPharma’s common stock is listed on
the Nasdaq Capital Market under the symbol SNBP.
Contact Information:
Investors:
James Carbonara
Hayden IR
(646) 755-7412
James@haydenir.com
Media:
Tammy Groene – Sun BioPharma, Inc.
952-479-1196
Sun BioPharma (NASDAQ:SNBP)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Sun BioPharma (NASDAQ:SNBP)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024